Is Moderna (MRNA) Headed for a Breakout?

Moderna, Inc. (MRNA) is a commercial-stage biotech company. The firm’s mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 24 mRNA development programs as of early 2021, with 13 of these in clinical trials…

Moderna’s (MRNA) COVID-19 vaccine has demonstrated strong uptake in several countries where it received authorization for temporary use over the past few months. Management expects more than $19 billion in vaccine sales for 2021. In addition, it has advance purchase agreements in place with several countries for 2022 worth $20 billion.

As of the most recent quarter, MRNA had $8 billion in cash compared to only $433 million in long-term debt. From a growth standpoint, sales surged 6,456% year over year in the second quarter. Analysts expected revenue to surge another 8,216% year over year in the current quarter.

These growth figures have led to a Growth Grade of B in our POWR Ratings system. In terms of valuation, the stock appears undervalued based on its forward P/E of 13.81. The stock was showing bullish momentum from April to early August, but performance has been mixed since, as you can see from the chart below.

Take a look at the 6-month chart of MRNA below with my added notations…

See chart and continue reading at